Press Releases April 24, 2026 06:30 AM

BOSS Zhipin's Ongoing Share Repurchases Cross the RMB1 Billion Mark in 2026

KANZHUN LIMITED exceeds RMB1 billion in share repurchases in 2026, reinforcing shareholder value commitment.

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
BZ

KANZHUN LIMITED, trading as BOSS Zhipin, continues its aggressive share repurchase program in 2026, crossing RMB1 billion invested in buybacks year-to-date. Recent purchases included 597,224 shares using RMB27.3 million, demonstrating strong commitment to enhancing shareholder value.

BOSS Zhipin's Ongoing Share Repurchases Cross the RMB1 Billion Mark in 2026
BZ
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • KANZHUN LIMITED has repurchased over RMB1 billion worth of shares so far in 2026.
  • On April 23, the company used RMB27.3 million to buy back 597,224 ordinary shares.
  • The ongoing share repurchase program signals confidence in the company’s future and benefits shareholders by potentially boosting stock value.

BEIJING, April 24, 2026 (GLOBE NEWSWIRE) -- KANZHUN LIMITED (“BOSS Zhipin” or the “Company”) (Nasdaq: BZ; HK: 2076) today announced the continued execution of its share repurchase program, utilizing over RMB27.3 million to repurchase 597,224 ordinary shares on April 23. With this latest repurchase, the Company has deployed over RMB1 billion toward share repurchases year-to-date in 2026. This effort underscores the Company's ongoing commitment to delivering value to shareholders.


Risks

  • Future share repurchase activity depends on the company's financial health and market conditions, which may vary.
  • Large allocation of capital to buybacks could limit funds available for growth initiatives or investments.
  • Market volatility or downturns could negatively affect repurchase efficacy or shareholder returns.

More from Press Releases

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026 ROMA Green Finance Establishes Dedicated Artificial Intelligence and High-Performance Computing Infrastructure Investment Vertical Jun 12, 2026